Telix Pharmaceuticals to acquire RLS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2024
0mins
Should l Buy ?
Acquisition Announcement: Telix Pharmaceuticals has agreed to acquire RLS, a radiopharmacy network, from its parent company for $230 million upfront, with potential additional payments of up to $20 million based on performance milestones.
Strategic Expansion: This acquisition will enhance Telix's manufacturing capabilities in North America and establish a new radiometal production network to support its operations and strategic partners.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
